Psilocybin and lysergic acid diethylamide (LSD) act as potent serotonin 5-HT2A receptor agonists, which are believed to modulate neurotransmitter pathways and potentially interrupt the pathological neurological processes underlying cluster headaches. These substances have demonstrated potential in reducing cluster headache frequency and intensity through their ability to disrupt aberrant neural signaling and potentially reset the hypothalamic mechanisms thought to be involved in cluster headache pathogenesis.